TD Cowen lowered the firm’s price target on Medpace (MEDP) to $372 from $413 and keeps a Buy rating on the shares. The firm said the company expects cancellations from 1Q through 3Q to carry over and depress book-to-bill from 4Q24 to 2Q25 leaving return to 1.2x unlikely until 2H25 at the earliest.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP:
- Medpace downgraded to Neutral from Outperform at Baird
- Closing Bell Movers: Medpace down 11% after cutting FY24 revenue guide
- Medpace reports Q3 EPS $3.01, consensus $2.78
- Medpace raises FY24 EPS view to $11.71-$12.09 from $11.24-$11.93
- Options Volatility and Implied Earnings Moves Today, October 21, 2024